Post-Marketing Surveillance Study of the Safety and Efficacy of Nalfurafine (Capsules 2.5 μg, Oral Dispersing Tablets 2.5 μg) in 1186 Patients with Chronic Liver Disease and Intractable Pruritus

BACKGROUND: Nalfurafine (Remitch(®), Toray Industries, Inc.) is a selective κ-receptor agonist approved in Japan for the improvement of pruritus in patients with chronic liver diseases (only when existing treatments bring insufficient efficacy) in May 2015. METHODS: A post-marketing Specific Drug Us...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshitani, Hiroshi, Ito, Junko, Kozono, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075016/
https://www.ncbi.nlm.nih.gov/pubmed/35530746
http://dx.doi.org/10.2147/HMER.S352775

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075016/
https://www.ncbi.nlm.nih.gov/pubmed/35530746
http://dx.doi.org/10.2147/HMER.S352775

Ejemplares similares